- Home
- MVST vs IPHA Comparison
MVST vs IPHA Comparison
Compare MVST & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | IPHA |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.9M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MVST | IPHA |
|---|---|---|
| Price | $3.14 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | ★ 4.3M | 26.4K |
| Earning Date | 11-10-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,504,000.00 | $14,839,695.00 |
| Revenue This Year | $24.19 | $22.29 |
| Revenue Next Year | $17.70 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $1.09 | $1.60 |
| 52 Week High | $7.12 | $2.63 |
Technical Indicators
Market Signals| Indicator | MVST | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 44.44 |
| Support Level | $2.73 | $1.70 |
| Resistance Level | $3.16 | $1.85 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 78.46 | 38.71 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.